Novo Nordisk Foundation grants EUR 300m to new research center

The Novo Nordisk Foundation's biggest research center investment to date, a sum of EUR 300m, will enable future stem cell research. The grant supports the dream of curing chronic diseases, says Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation.

Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation | Photo: Gregers Tycho/ERH

An investment of EUR 300m over ten years has been granted to a new international stem cell research center, dubbed Renew – the sum is the biggest grant that the Novo Nordisk Foundation has ever given to a research center, Danish media Berlingske reports.

The center aims to realize dream of treating incurable diseases such as kidney failure, heart failure, Parkinson's and diabetes with stem cells. A new national upscaling center for stem cells is also sponsored by the Novo Nordisk Foundation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs